Combination of avutometinib and defactinib offers new option where chemotherapy has often failed
Combination of avutometinib and defactinib offers new option where chemotherapy has often failed
TRANQUILITY trial results strengthen case for pacibekitug as a potential quarterly IL-6 inhibitor for cardiovascular inflammation in chronic …
Dual clinical studies reveal statistically meaningful benefits for patients with MSA, highlighting a leap forward for disease-modifying treatment …
Phase III ASCENT-04/KEYNOTE-D19 trial reveals meaningful PFS improvement with a novel antibody-drug conjugate/immunotherapy combo
Enhertu combo shows promise in metastatic breast cancer while Arvinas reveals hopeful data on a novel lymphoma proteolysis …
A key regulation is poised to reshape clinical research in Britain—reducing red tape, elevating patient voices and strengthening …
New data reveals that smaller biopharma players are gaining ground in innovation, contributing a growing share of first-in-class …
A landmark study from MHRA and University of Liverpool reveals the UK’s leadership in drug development and outlines …
An investigational RNA-based therapy shows significant reduction in disease-causing protein levels—potentially a meaningful step forward in treating Huntington’s …
Topical laquinimod reaches posterior eye tissues with dose-related distribution and good tolerability in patients preparing for vitrectomy
Already a subscriber? Log in